Phase II trial of VP-16-213 in non-small-cell lung cancer

L. M. Itri, Richard J. Gralla, R. A. Chapman, D. P. Kelsen, E. S. Casper, R. B. Golbey

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Fifty-one patients with metastatic non-small-cell lung cancer (NSCLC) were treated with VP-16-213 (4'-demethylepipodophyllotoxin) during a phase II trial. Of the 49 patients who had adequate trials, 2 patients achieved a partial response (PR), for an overall 4% major response rate. The median Karnofsky performance status (PS) was 80%; 85.7% of patients had adenocarcinoma and 14.2% had epidermoid carcinoma. Prior treatment with chemotherapy may have adversely affected response rate; the two responses occurred among the 25 previously untreated patients, while no responses were seen in patients who had previously received chemotherapy. Myelosuppression was the most frequent side effect and two drug-related deaths due to septicemia occurred. Other toxic effects noted included anorexia, nausea and vomiting, partial alopecia, and, in one patient, chills and hypotension during drug infusion. We conclude that VP-16-213 has minimal activity as a single agent in NSCLC.

Original languageEnglish (US)
Pages (from-to)45-47
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume5
Issue number1
StatePublished - 1982
Externally publishedYes

Fingerprint

Etoposide
Non-Small Cell Lung Carcinoma
Karnofsky Performance Status
Drug Therapy
Chills
Poisons
Alopecia
Anorexia
Drug-Related Side Effects and Adverse Reactions
Hypotension
Nausea
Vomiting
Squamous Cell Carcinoma
Sepsis
Adenocarcinoma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Itri, L. M., Gralla, R. J., Chapman, R. A., Kelsen, D. P., Casper, E. S., & Golbey, R. B. (1982). Phase II trial of VP-16-213 in non-small-cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 5(1), 45-47.

Phase II trial of VP-16-213 in non-small-cell lung cancer. / Itri, L. M.; Gralla, Richard J.; Chapman, R. A.; Kelsen, D. P.; Casper, E. S.; Golbey, R. B.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 5, No. 1, 1982, p. 45-47.

Research output: Contribution to journalArticle

Itri, LM, Gralla, RJ, Chapman, RA, Kelsen, DP, Casper, ES & Golbey, RB 1982, 'Phase II trial of VP-16-213 in non-small-cell lung cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 5, no. 1, pp. 45-47.
Itri LM, Gralla RJ, Chapman RA, Kelsen DP, Casper ES, Golbey RB. Phase II trial of VP-16-213 in non-small-cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials. 1982;5(1):45-47.
Itri, L. M. ; Gralla, Richard J. ; Chapman, R. A. ; Kelsen, D. P. ; Casper, E. S. ; Golbey, R. B. / Phase II trial of VP-16-213 in non-small-cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1982 ; Vol. 5, No. 1. pp. 45-47.
@article{f96cde59b9564143a104d70ff74ae612,
title = "Phase II trial of VP-16-213 in non-small-cell lung cancer",
abstract = "Fifty-one patients with metastatic non-small-cell lung cancer (NSCLC) were treated with VP-16-213 (4'-demethylepipodophyllotoxin) during a phase II trial. Of the 49 patients who had adequate trials, 2 patients achieved a partial response (PR), for an overall 4{\%} major response rate. The median Karnofsky performance status (PS) was 80{\%}; 85.7{\%} of patients had adenocarcinoma and 14.2{\%} had epidermoid carcinoma. Prior treatment with chemotherapy may have adversely affected response rate; the two responses occurred among the 25 previously untreated patients, while no responses were seen in patients who had previously received chemotherapy. Myelosuppression was the most frequent side effect and two drug-related deaths due to septicemia occurred. Other toxic effects noted included anorexia, nausea and vomiting, partial alopecia, and, in one patient, chills and hypotension during drug infusion. We conclude that VP-16-213 has minimal activity as a single agent in NSCLC.",
author = "Itri, {L. M.} and Gralla, {Richard J.} and Chapman, {R. A.} and Kelsen, {D. P.} and Casper, {E. S.} and Golbey, {R. B.}",
year = "1982",
language = "English (US)",
volume = "5",
pages = "45--47",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Phase II trial of VP-16-213 in non-small-cell lung cancer

AU - Itri, L. M.

AU - Gralla, Richard J.

AU - Chapman, R. A.

AU - Kelsen, D. P.

AU - Casper, E. S.

AU - Golbey, R. B.

PY - 1982

Y1 - 1982

N2 - Fifty-one patients with metastatic non-small-cell lung cancer (NSCLC) were treated with VP-16-213 (4'-demethylepipodophyllotoxin) during a phase II trial. Of the 49 patients who had adequate trials, 2 patients achieved a partial response (PR), for an overall 4% major response rate. The median Karnofsky performance status (PS) was 80%; 85.7% of patients had adenocarcinoma and 14.2% had epidermoid carcinoma. Prior treatment with chemotherapy may have adversely affected response rate; the two responses occurred among the 25 previously untreated patients, while no responses were seen in patients who had previously received chemotherapy. Myelosuppression was the most frequent side effect and two drug-related deaths due to septicemia occurred. Other toxic effects noted included anorexia, nausea and vomiting, partial alopecia, and, in one patient, chills and hypotension during drug infusion. We conclude that VP-16-213 has minimal activity as a single agent in NSCLC.

AB - Fifty-one patients with metastatic non-small-cell lung cancer (NSCLC) were treated with VP-16-213 (4'-demethylepipodophyllotoxin) during a phase II trial. Of the 49 patients who had adequate trials, 2 patients achieved a partial response (PR), for an overall 4% major response rate. The median Karnofsky performance status (PS) was 80%; 85.7% of patients had adenocarcinoma and 14.2% had epidermoid carcinoma. Prior treatment with chemotherapy may have adversely affected response rate; the two responses occurred among the 25 previously untreated patients, while no responses were seen in patients who had previously received chemotherapy. Myelosuppression was the most frequent side effect and two drug-related deaths due to septicemia occurred. Other toxic effects noted included anorexia, nausea and vomiting, partial alopecia, and, in one patient, chills and hypotension during drug infusion. We conclude that VP-16-213 has minimal activity as a single agent in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0020325063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020325063&partnerID=8YFLogxK

M3 - Article

C2 - 7081137

AN - SCOPUS:0020325063

VL - 5

SP - 45

EP - 47

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -